We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+150.31%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
+$412M
Cap. Flow
+$25.7M
Cap. Flow %
2.41%
Top 10 Hldgs %
48.66%
Holding
270
New
60
Increased
70
Reduced
50
Closed
53

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$27.6M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$20.5M
3
ROIV icon
Roivant Sciences
ROIV
+$17.4M
4
ETNB
89bio
ETNB
+$12.6M
5
JANX icon
Janux Therapeutics
JANX
+$7.04M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$105M
2
PRTA icon
Prothena Corp
PRTA
+$14.6M
3
CGON icon
CG Oncology
CGON
+$7.97M
4
SAGE
Sage Therapeutics
SAGE
+$6.58M
5
VERV
Verve Therapeutics
VERV
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 83.19%
2 Financials 1.65%
3 Communication Services 0.09%
4 Consumer Discretionary 0.09%
5 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCAX
176
Bicara Therapeutics
BCAX
$1.84B
$216K 0.02%
13,705
-9,170
-40% -$103K
IFRX icon
177
InflaRx
IFRX
$271M
$214K 0.02%
+159,479
New +$169K
REPL icon
178
CALL
Replimune Group
REPL
$1.01B
$210K 0.02%
+50,000
New +$320K
DAWN
179
DELISTED
Day One Biopharmaceuticals
DAWN
$198K 0.02%
28,023
– –
HELP
180
Cybin Inc
HELP
$720M
$196K 0.02%
+33,278
New +$236K
CMPX icon
181
Compass Therapeutics
CMPX
$387M
$175K 0.02%
50,000
+25,000
+100% +$79K
RXRX icon
182
Recursion Pharmaceuticals
RXRX
$1.72B
$171K 0.02%
35,000
– –
PEPG icon
183
PepGen
PEPG
$197M
$170K 0.02%
36,842
+16,490
+81% +$26.6K
KPTI icon
184
Karyopharm Therapeutics
KPTI
$48M
$164K 0.02%
+25,000
New +$135K
VYGR icon
185
Voyager Therapeutics
VYGR
$198M
$163K 0.02%
35,000
-44,945
-56% -$163K
ATYR
186
PUT
aTyr Pharma
ATYR
$50.1M
$161K 0.02%
222,500
+172,500
+345% +$782K
TARA icon
187
Protara Therapeutics
TARA
$232M
$153K 0.01%
35,223
-87,467
-71% -$283K
ACHV icon
188
Achieve Life Sciences
ACHV
$683M
$151K 0.01%
47,800
+4,627
+11% +$12.7K
CLOV icon
189
Clover Health Investments
CLOV
$2.51B
$148K 0.01%
48,300
– –
FDMT icon
190
4D Molecular Therapeutics
FDMT
$562M
$145K 0.01%
+16,712
New +$99.9K
GOSS icon
191
CALL
Gossamer Bio
GOSS
$87M
$145K 0.01%
+55,100
New +$121K
PMVP icon
192
PMV Pharmaceuticals
PMVP
$63.5M
$141K 0.01%
101,008
– –
GBIO
193
DELISTED
Generation Bio
GBIO
$136K 0.01%
+22,144
New +$115K
CRBP icon
194
Corbus Pharmaceuticals
CRBP
$188M
$129K 0.01%
+10,200
New +$97K
ATYR
195
aTyr Pharma
ATYR
$50.1M
$126K 0.01%
+175,000
New +$793K
MLTX icon
196
CALL
MoonLake Immunotherapeutics
MLTX
$1.55B
$122K 0.01%
+17,000
New +$886K
KALV
197
DELISTED
KalVista Pharmaceuticals
KALV
$122K 0.01%
10,000
– –
IOVA icon
198
CALL
Iovance Biotherapeutics
IOVA
$2.83B
$109K 0.01%
+50,000
New +$118K
OGN icon
199
Organon & Co
OGN
$3.57B
$107K 0.01%
10,000
– –
SLN
200
Silence Therapeutics
SLN
$564M
$96.8K 0.01%
18,643
– –
6 7
8
9 10

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, ADAR1 Capital Management held 270 positions worth $1.06B, up 63% from $652M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

ADAR1 Capital Management's Q3 2025 filing shows 60 new, 70 increased, 50 reduced and 53 closed positions. Its largest new stake was Invivyd: 7,370,987 shares worth $8.11M. The largest sale was Abivax, an estimated $105M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Financials and Communication Services.

  • ADAR1 Capital Management's largest Q3 2025 buy was Invivyd: 7,370,987 shares worth $8.11M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2025, an estimated $27.6M increase.
  • ADAR1 Capital Management's biggest Q3 2025 reduction was Abivax, cutting an estimated $105M.
  • ADAR1 Capital Management fully exited Sage Therapeutics in Q3 2025, selling an estimated $6.58M.
  • ADAR1 Capital Management's ten largest holdings make up 49% of its $1.06B portfolio in Q3 2025.
  • ADAR1 Capital Management opened 60 new positions and closed 53 in Q3 2025.
  • ADAR1 Capital Management's portfolio value rose 63% quarter-over-quarter to $1.06B.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.